DUALITYBIO-B has been included in the Hang Seng Composite Index and is expected to become a target for the Hong Kong Stock Connect
DUALITYBIO-B has been included in the Hang Seng Composite Index, with the change to be implemented after the market closes on September 5 and effective from September 8. Huatai Securities pointed out that the company meets the standards for market capitalization, liquidity, and listing time, and is expected to be included in the Hong Kong Stock Connect. Its key product DB-1310 has been granted Fast Track designation by the FDA for the treatment of certain types of advanced non-small cell lung cancer
According to the Zhitong Finance APP, on August 22, the Hang Seng Index Company announced the results of the quarterly review of the Hang Seng Index series as of June 30, 2025, in which DUALITYBIO-B (09606) was included in the Hang Seng Composite Index. The changes will be implemented after the market closes on September 5 (Friday) and will take effect on September 8 (Monday). At that time, the Shanghai and Shenzhen Stock Exchanges will adjust the scope of investable stocks under the Hong Kong Stock Connect accordingly. According to a research report from Huatai Securities, DUALITYBIO-B may be included in the Hong Kong Stock Connect as it meets a series of criteria including market capitalization, liquidity, and listing time.
DUALITYBIO announced that its key product DB-1310 (an antibody-drug conjugate targeting human epidermal growth factor receptor 3 (HER3)) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) who have disease progression during or after treatment with third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy, and who carry EGFR exon 19 deletions or L858R mutations.
It is reported that DB-1310 is a next-generation ADC product targeting HER3 developed using the company's proprietary DITAC technology platform. In June 2025, DUALITYBIO presented the first human Phase I/IIa clinical study (NCT05785741) data of DB-1310 at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, with Dr. Aaron E. Lisberg from the University of California, Los Angeles (UCLA) delivering the oral presentation. The results showed that DB-1310 demonstrated encouraging efficacy and controllable safety in patients with advanced solid tumors who failed standard treatment
